FDA Prepares For Issues for Treatment of Parenteral Nutrition Associated Liver Disease
This article was originally published in RPM Report
FDA is planning an advisory committee discussion of the “need for and design of” clinical trials for parenteral nutrition products in the US. The panel was scheduled for October 15 but was cancelled for logistical reasons. The discussion is likely to build on a September public workshop that wrestled with the unique challenges in developing new formulations of vital supportive therapies. In this article, an executive with one of the firms with different parenteral products outside the US (Fresenius/Kabi) outlines the issues raised in the workshop and the reaction of expert panelists.
You may also be interested in...
From the conception of the REMS in the FDAAA Act of 2007, Congress was concerned that giving FDA authority to impose new post-marketing controls could raise competitive issues about market access for generics. Congress was right to be concerned. Despite a specific admonition in FDAAA to prevent use of the most restrictive REMS programs to prevent new competition, strategies to extend product exclusivity have emerged and the competitive landscape has changed.